FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387495021> ?p ?o ?g. }

• W4387495021 abstract "Abstract Background Lisdexamfetamine (LDX) and Methylphenidate (MPH) are stimulant agents that have been shown to provide significant benefits in the management of attention-deficit/hyperactivity disorder (ADHD) in patients. Aim This study aimed to assess the cost-effectiveness and the budget impact of LDX compared to MPH as the first-line treatment for ADHD. Methods A one-year cost-effectiveness analysis (CEA) was conducted to compare the effects of LDX and MPH in reducing disease symptoms and patient costs and improving quality of life (QoL) from a social perspective. Clinical data were obtained using the EQ-5D questionnaire. In contrast, economic data were sourced from the official website of the Iranian Food and Drug Association (FDA), the national book of tariffs, and specific questionnaires designed to evaluate patients' direct and indirect costs. 197 patients were included in the study, including individuals who sought psychiatric evaluation at a hospital in Mashhad and those who obtained ADHD medications from governmental pharmacies. The cost-effectiveness of the study medicine was assessed using the decision tree method, and the results were presented as the Incremental Cost-Effectiveness Ratio (ICER). Deterministic Sensitivity Analysis (DSA) and Probabilistic Sensitivity Analysis (PSA) were performed to assess the robustness of the findings. Additionally, a Budget Impact Analysis (BIA) was conducted over five years, considering three different scenarios, to evaluate the financial implications of incorporating LDX into the national pharmaceutical system. Results The ICER for LDX therapy compared to MPH was estimated at USD 264.28 (with an incremental cost of USD 54.9, incremental effectiveness of 0.208, and Quality-Adjusted Life Years (QALYs) gained of 0.765). The PSA indicated a 0.994% probability of LDX being cost-effective, considering a threshold of USD 2450 per QALY. Furthermore, the DSA revealed that the acquisition cost of LDX influenced the model's sensitivity. The BIA demonstrated that incorporating LDX into Iran's healthcare system would result in a financial burden of approximately $368,566 in the first year, representing an additional cost of $11,154 compared to the non-availability of this medicine and the use of previous medications. It is projected that by 2027, the financial burden of treating ADHD with LDX will reach approximately USD 443,879 over five years, amounting to an increase of $71,154 compared to the absence of this medicine. Conclusion From a social perspective, the inclusion of LDX in the treatment regimen for ADHD is associated with higher costs and an increased financial burden. However, based on our analysis, LDX appears to be a cost-effective choice for managing ADHD in Iran when compared to MPH." @default.
• W4387495021 created "2023-10-11" @default.
• W4387495021 creator A5025053518 @default.
• W4387495021 creator A5025772810 @default.
• W4387495021 creator A5047476297 @default.
• W4387495021 creator A5064232215 @default.
• W4387495021 creator A5080572893 @default.
• W4387495021 date "2023-10-10" @default.
• W4387495021 modified "2023-10-14" @default.
• W4387495021 title "Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran" @default.
• W4387495021 cites W1751633684 @default.
• W4387495021 cites W1926410314 @default.
• W4387495021 cites W2001183909 @default.
• W4387495021 cites W2001362670 @default.
• W4387495021 cites W2016511885 @default.
• W4387495021 cites W2038601354 @default.
• W4387495021 cites W2040988519 @default.
• W4387495021 cites W2041139943 @default.
• W4387495021 cites W2052904414 @default.
• W4387495021 cites W2056434954 @default.
• W4387495021 cites W2057166186 @default.
• W4387495021 cites W2058562698 @default.
• W4387495021 cites W2081678288 @default.
• W4387495021 cites W2085570002 @default.
• W4387495021 cites W2101112582 @default.
• W4387495021 cites W2107612326 @default.
• W4387495021 cites W2108676444 @default.
• W4387495021 cites W2113065987 @default.
• W4387495021 cites W2114290463 @default.
• W4387495021 cites W2119679249 @default.
• W4387495021 cites W2120173188 @default.
• W4387495021 cites W2121027929 @default.
• W4387495021 cites W2140548090 @default.
• W4387495021 cites W2140774080 @default.
• W4387495021 cites W2143445712 @default.
• W4387495021 cites W2146964018 @default.
• W4387495021 cites W2148978240 @default.
• W4387495021 cites W2160975086 @default.
• W4387495021 cites W2162012775 @default.
• W4387495021 cites W2162731592 @default.
• W4387495021 cites W2163322724 @default.
• W4387495021 cites W2166577179 @default.
• W4387495021 cites W2168058010 @default.
• W4387495021 cites W2511287670 @default.
• W4387495021 cites W2520294733 @default.
• W4387495021 cites W2575483126 @default.
• W4387495021 cites W2763418337 @default.
• W4387495021 cites W2777742400 @default.
• W4387495021 cites W2789958560 @default.
• W4387495021 cites W2886241630 @default.
• W4387495021 cites W2901798356 @default.
• W4387495021 cites W2991491584 @default.
• W4387495021 cites W2992975468 @default.
• W4387495021 cites W2994107101 @default.
• W4387495021 cites W3031352486 @default.
• W4387495021 cites W3175341338 @default.
• W4387495021 cites W3180750489 @default.
• W4387495021 cites W3207759740 @default.
• W4387495021 cites W3208500803 @default.
• W4387495021 cites W4213266521 @default.
• W4387495021 cites W4213383170 @default.
• W4387495021 cites W4253680259 @default.
• W4387495021 cites W4293162733 @default.
• W4387495021 cites W4313304232 @default.
• W4387495021 cites W4367298898 @default.
• W4387495021 cites W4385635519 @default.
• W4387495021 doi "https://doi.org/10.1186/s13034-023-00664-1" @default.
• W4387495021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37817221" @default.
• W4387495021 hasPublicationYear "2023" @default.
• W4387495021 type Work @default.
• W4387495021 citedByCount "0" @default.
• W4387495021 crossrefType "journal-article" @default.
• W4387495021 hasAuthorship W4387495021A5025053518 @default.
• W4387495021 hasAuthorship W4387495021A5025772810 @default.
• W4387495021 hasAuthorship W4387495021A5047476297 @default.
• W4387495021 hasAuthorship W4387495021A5064232215 @default.
• W4387495021 hasAuthorship W4387495021A5080572893 @default.
• W4387495021 hasBestOaLocation W43874950211 @default.
• W4387495021 hasConcept C104863432 @default.
• W4387495021 hasConcept C112930515 @default.
• W4387495021 hasConcept C118552586 @default.
• W4387495021 hasConcept C138816342 @default.
• W4387495021 hasConcept C142724271 @default.
• W4387495021 hasConcept C159110408 @default.
• W4387495021 hasConcept C2776125615 @default.
• W4387495021 hasConcept C2777112843 @default.
• W4387495021 hasConcept C2779900020 @default.
• W4387495021 hasConcept C2779951463 @default.
• W4387495021 hasConcept C2780557958 @default.
• W4387495021 hasConcept C2780783007 @default.
• W4387495021 hasConcept C3019080777 @default.
• W4387495021 hasConcept C512399662 @default.
• W4387495021 hasConcept C515549039 @default.
• W4387495021 hasConcept C524218345 @default.
• W4387495021 hasConcept C71924100 @default.
• W4387495021 hasConceptScore W4387495021C104863432 @default.
• W4387495021 hasConceptScore W4387495021C112930515 @default.
• W4387495021 hasConceptScore W4387495021C118552586 @default.
• W4387495021 hasConceptScore W4387495021C138816342 @default.
• W4387495021 hasConceptScore W4387495021C142724271 @default.

• next